

## PROGRAM

**September 22<sup>nd</sup> (Thursday), 2016**

7:55~8:00

### Opening Remark

Shuichi Kaneko (President of the Conference)

8:00~9:00 at Conference Room 1

### Session 1-1 Cancer Immunotherapy for hepatocellular carcinoma

(MSD K.K.)

*Chair: Kazuaki Chayama*

*(Professor, Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University)*

#### 1. Alpha Fetoprotein and Immunotherapy for Hepatocellular Carcinoma

Lisa H. Butterfield

(Professor of Medicine, Surgery and Immunology Director, UPCI Immunologic Monitoring and Cellular Products Laboratory)

#### 2. Hepatocellular carcinoma: current status and future perspectives

Ann-Lii Cheng

(Distinguished professor and Director, National Taiwan University Cancer Center)

9:00~10:00 at Conference Room 1

### Session 1-2 Cancer Immunotherapy for hepatocellular carcinoma

*Chair: Kazuhiko Koike*

*(Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo)*

#### 1. The promise of immunotherapy in the treatment of hepatocellular carcinoma

Anthony El-Khoueiry

(Section of Gastrointestinal Oncology, Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Keck School of Medicine)

#### 2. Immune-related response and toxicity evaluations: Imaging as a common language for cancer immunotherapy

Mizuki Nishino

(Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School)

8:00~10:05 at Conference Room 2

## **Session 2 Curative treatment for early stage HCC**

*Chairs: Norihiro Kokudo*

*(Hepatobiliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo)*

*Tatsuya Yamashita*

*(Department of Gastroenterology, Kanazawa University Hospital)*

### 1. Treatment for early hepatocellular carcinoma

Yutaka Midorikawa

(Department of Digestive surgery, Nihon University School of Medicine)

### 2. RFA

Shigehiro Kokubu

(Institute for Liver Disease Minimal Invasive Treatment, Shin-Yurigaoka General Hospital)

### 3. Irreversible electroporation for liver cancer: initial clinical experience in Japan

Katsutoshi Sugimoto

(Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, Japan)

### 4. Role of liver resection for small hepatocellular carcinoma

Norihiro Kokudo

(Hepatobiliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo)

### 5. Liver transplantation for early stage hepatocellular carcinoma

Kiyoshi Hasegawa

(Hepatobiliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo)

10:00~12:30 at Conference Room 1

## **Session 3 Immune checkpoints blockade and beyond**

*Chairs: Tetsuo Takehara*

*(Osaka University, Graduate School of Medicine, Department of Gastroenterology and Hepatology)*

*Kouji Matsushima*

*(Department of Molecular Preventive Medicine, Graduate School of Medicine, The University of Tokyo)*

### 1. History of PD-1 and perspectives of PD-1 checkpoint blockade cancer immunotherapy

Nagahiro Minato

(Graduate School of Medicine, Kyoto University)

2. Personalized combinatorial cancer immunotherapy beyond immune-checkpoint blockade

Yutaka Kawakami

(Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine)

3. De-fucosylated anti-CCR4 and CD4 antibodies for cancer immunotherapy

Kouji Matsushima

(Department of Molecular Preventive Medicine, Graduate School of Medicine, The University of Tokyo)

4. A Novel Combination Immunotherapy Cures Tumor Highly Resistant to Immune Checkpoint Blockade

Hiroshi Shiku

(Mie University Center for Comprehensive Cancer Immunotherapy)

5. Immunotherapy for hepatocellular carcinoma

Eishiro Mizukoshi

(Department of Gastroenterology, Graduate School of Medicine, Kanazawa University)

10:05~12:05 at Conference Room 2

**Session 4 Strategies for Intermediate stage HCC**

(Eisai Co., Ltd.)

*Chairs: Osamu Matsui*

*(Professor Emeritus, Kanazawa University)*

*Kwang-Hyub Han*

*(Department of Internal Medicine, Yonsei Univ. College of Medicine)*

1. Sub-classification of intermediate stage HCC and treatment strategy

Kwang-Hyub Han

(Department of Internal Medicine, Yonsei Univ. College of Medicine)

2. Significance and strategies of intermediate stage of HCC

Kenji Ikeda

(Department of Hepatology, Toranomon Hospital, Tokyo, JAPAN)

3. How to manage the up to seven In / Out

Koichiro Yamakado

(Department of Radiology, Hyogo College of Medicine)

4. New Subclassification and Treatment Strategy for Intermediate Stage HCC

Masatoshi Kudo

(Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine)

12:05~12:30 at Conference Room 2

### **Special Lecture**

*Chair: Munehito Machida*

*(Department for Global Health, Kanazawa University School of Medicine)*

#### **Regional Action Plan for Viral Hepatitis in the Western Pacific 2016-2020**

Ying-Ru Lo

(HIV, Hepatitis and STI Unit, Division of Communicable Diseases, World Health Organization Regional Office for the Western Pacific, Manila, The Philippines.)

12:40~13:30 at Conference Room 1

### **Luncheon Seminar 1**

(Gilead Sciences K.K.)

*Chair: Keisuke Hino*

*(Professor, Department of Hepatology and Pancreatology, Kawasaki Medical School)*

#### **A New Era of Treatment for Hepatitis C Virus Infection**

Akio Ido

(Professor, Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan)

12:40~13:30 at Conference Room 2

### **Luncheon Seminar 2**

(Otsuka Pharmaceutical Co., Ltd.)

*Chair: Kazuhiko Koike*

*(Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo)*

#### **New insight for complication of cirrhosis, edema and ascites, encephalopathy and muscle cramps**

Namiki Izumi

(Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital)

13:40~16:40 at Conference Room 1

**Session 5 Pathogenesis of HCC: evolving concept and future perspective**

*Chairs: Yasunari Nakamoto*

*(Gastroenterology and Neurology, Faculty of Medical Sciences, University of Fukui)*

*Xin Wei Wang*

*(Laboratory of Human Carcinogenesis, Center for Cancer Research, U.S. National Cancer Institute)*

**1. Modeling human liver development, chronic hepatitis virus infection, immunopathogenesis and therapy in mice**

Lishan Su

(Professor, Department of Microbiology and Immunology, Lineberger Comprehensive Cancer Center, School of Medicine, The University of North Carolina at Chapel Hill)

**2. New Targets for the Prevention and Treatment of HCC through an Integrated Approach**

Lopa Mishra

(Director Center for Translational Medicine, Professor of Surgery, GW Cancer Center, George Washington University, Washington DC)

**3. Molecular classification of hepatocellular carcinoma**

Xin Wei Wang

(Laboratory of Human Carcinogenesis, Center for Cancer Research, U.S. National Cancer Institute)

**4. Cancer Stem Cells in Hepatocellular Carcinoma**

Taro Yamashita

(Departments of General Medicine / Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan)

**5. Integrated analysis of genetic and epigenetic aberrations in hepatocellular carcinoma**

Genta Nagae

(Genome Science Division, Research Center for Advanced Science and Technology (RCAST), the University of Tokyo)

**6. A novel biomarker for early diagnosis of hepatocellular carcinoma**

Naohiko Koshikawa

(Division of Cancer Cell Research, Kanagawa Cancer Center Research Institute.)

13:40~15:20 at Conference Room 2

## **Session 6 Challenge of Treatment for Advanced HCC**

*Chairs: Namiki Izumi*

*(Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital)*

*Mitsuhiko Moriyama*

*(Institute of Gastroenterology, Nihon University School of Medicine)*

1. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma  
Takeshi Terashima  
(Department of Gastroenterology, Kanazawa University Hospital)
2. A novel chemo-surgical treatment strategy for advanced hepatocellular carcinoma with percutaneous isolated hepatic perfusion (PIHP)  
Yonson Ku  
(Kobe University Graduate School of Medicine)
3. The role of radiotherapy for hepatocellular carcinoma accompanying macrovascular invasion: combination with hepatic arterial infusion chemotherapy  
Hiroshi Aikata  
(Department of Gastroenterology and Metabolism, Hiroshima University Hospital)
4. Proton beam therapy for hepatocellular carcinoma  
Hideyuki Sakurai  
(Department of Radiation Oncology & Proton Medical Research Center (PMRC), University of Tsukuba, Japan)

15:20~16:35 at Conference Room 2

## **Session 7 Clinical trial design and approval of novel treatment in Japan**

*Chairs: Satoshi Mochida*

*(Department of Gastroenterology and Hepatology, Saitama Medical University)*

*Junji Furuse*

*(Department of Medical Oncology, Kyorin University School of Medicine)*

1. New Ideas- From Enrichment Strategies to Regenerative Medicine  
Masahiro Takeuchi  
(Division of Biostatistics, Department of Clinical Medicine, Kitasato University School of Pharmacy)
2. New governmental regulatory system for stem cell-based therapies  
Yasuhiro Homma  
(Deputy Director, Office for Research Promotion of Regenerative Medicine, Research and Development Division, Health Policy Bureau, MINISTRY OF HEALTH, LABOUR AND WELFARE GOVERNMENT OF JAPAN)

### 3. Approval strategies for medical devices

Koichi Aizawa

(Office of Medical Devices II, Pharmaceuticals and Medical Devices Agency (PMDA))

16:50~17:50 at Poster Session Room

#### **Poster Presentation & Discussion**

18:00~18:50 at Conference Room 1

#### **Evening Seminar 1**

(Takeda Pharmaceutical Company Limited.)

*Chair: Hajime Takikawa*

*(Department of Medicine, Teikyo University School of Medicine)*

#### **Paradigm shift in acid-related disease using P-CAB**

Takashi Kawai

(Endoscopy Center, Tokyo Medical University Hospital)

18:00~18:50 at Conference Room 2

#### **Evening Seminar 2**

(Taiho Pharmaceutical Co., LTD.)

*Chair: Yutaka Sasaki*

*(Professor and Chairman, Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University)*

#### **Systemic treatment for hepatobiliary and pancreatic cancer**

Hiroshi Ishii

(Director, Clinical Research Center, National Hospital Organization Shikoku Cancer Center)

19:00~21:00

#### **Welcome Reception**

## September 23<sup>rd</sup> (Friday), 2016

8:30~9:20 at Conference Room 1

### Morning Seminar 1

(Bristol-Myers Squibb K.K.)

*Chair: Satoshi Mochida*

*(Department of Gastroenterology & Hepatology, Saitama Medical University)*

Treatments in the Difficult-to-Treat Situations: renal failure and hemodialysis patients

Naoya Sakamoto

(Dept. of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido Univ.)

8:30~9:20 at Conference Room 2

### Morning Seminar 2

(Sumitomo Dainippon Pharma Co., Ltd / Toray Industries, Inc.)

*Chair: Tetsuo Takehara*

*(Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine)*

Design and Synthesis of Nalfurafine for an Antipruritic Drug for Chronic Liver Disease Patients and Kidney Dialysis Patients

Hiroshi Nagase

(International Institute for Integrative Sleep Medicine (IIIS), University of Tsukuba)

9:30~11:30 at Conference Room 1

### Session 8 Novel therapeutic targets in HCC

*Chairs: Shuhei Nishiguchi*

*(Division of Hepatobiliary and Pancreatic Diseases, Department of Internal Medicine, Hyogo College of Medicine)*

*Yutaka Sasaki*

*(Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University)*

#### 1. Overview of clinical trials of molecular target therapy for advanced hepatocellular carcinoma

Masafumi Ikeda

(Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan)



2. Biomarkers of molecular targeted therapy for HCC

Kazuto Nishio

(Department of Genome Biology, Kindai University School of Medicine)

3. Targeting TERT-RdRP in HCC

Kenkichi Masutomi

(Division of Cancer Stem Cell, National Cancer Center Research Institute)

4. Aurora kinase B as a diagnostic and therapeutic target in aggressive HCC

Shinji Tanaka

(Department of Molecular Oncology, Tokyo Medical and Dental University)

9:30~11:30 at Conference Room 2

**Session 9 From hepatitis to HCC, Global and regional strategies against hepatitis**

*Chairs: Nobuyuki Enomoto*

*(First Department of Internal Medicine, University of Yamanashi)*

*Hajime Takikawa*

*(Department of Medicine, Teikyo University School of Medicine)*

1. Strategies of the prevention and control against viral hepatitis in China

Hong Tang

(West China Hospital of Sichuan University)

2. Hepatocellular carcinoma in Vietnam population; diagnosis and current treatment.

Tran Ngoc Anh

(Gastroenterological Dept, Hanoi Medical University Hospital)

3. HCC diagnosis and treatment in Mongolia

Duger Davaadorj

(Mongolian National University of Medical Sciences)

4. From hepatitis to HCC, Global and regional strategies against hepatitis; Strategy in Japan

Nobuyuki Enomoto

(University of Yamanashi, Yamanashi, JAPAN)

5. Hepatocellular cancer: Epidemiology in Hawaii

Linda L. Wong

(Department of Surgery, University of Hawaii, John A. Burns School of Medicine)

6. FROM HEPATITIS TO HCC, GLOBAL AND REGIONAL STRATEGIES AGAINST HEPATITIS: STRATEGY IN THE USA.

Adrian M. Di Bisceglie

(Saint Louis University, St. Louis, MO, USA.)

## 7. Current Status of Viral Hepatitis in Mongolia

Tsendsuren Oyunsuren

(Laboratory of Molecular Biology, Institute of Biology, Mongolian Academy of Sciences, Ulaanbaatar, Mongolia)

11:45~12:35 at Conference Room 1

### Luncheon Seminar 3

(AbbVie GK)

*Chair: Masatoshi Kudo*

*(Professor and Chairman, Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine)*

#### Significance of anti-viral therapy in patients with HCV-related HCC

Kenji Ikeda

(Department of Hepatology, Toranomon Hospital, Tokyo)

11:45~12:35 at Conference Room 2

### Luncheon Seminar 4

(GlaxoSmithKline K.K.)

*Chair: Hiroshi Yotsuyanagi*

*(Professor, Division of Infectious Diseases, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo)*

#### IFN- $\lambda$ 3 induction by nucleotide analogs –A novel insight and potential target for HBV treatment–

Kazumoto Murata

(The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine)

13:20~15:20 at Conference Room 1

### Session 10 The position of molecular target therapy in HCC, now and future

(Bayer Yakuhin, Ltd.)

*Chairs: Masatoshi Kudo*

*(Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine)*

*Richard S. Finn*

*(Division of Hematology / Oncology, Department of Medicine / David Geffen School of Medicine at UCLA, University of California–Los Angeles)*

#### 1. An Update on the Molecular Target Therapy for Hepatocellular Carcinoma

Pei-Jer Chen

(Hepatitis Research Center, National Taiwan University Hospital)

2. Optimal management of advanced hepatocellular carcinoma based on real-life data

Kwang-Hyub Han

(Yonsei Liver Center, Severance Hospital, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea)

3. Treatment experience of sorafenib in Japanese hepatocellular carcinoma patients – When is the most suitable timing of starting sorafenib in clinical course?

Sadahisa Ogasawara

(Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan.)

4. The Development of Systemic Agents in HCC: Where the data exists and where it is lacking

Richard S. Finn

(Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, University of California-Los Angeles)

13:00~14:40 at Conference Room 2

**Session 11 Prevenson for HCC**

(\*CHUGAI PHARMACEUTICAL CO., LTD.)

*Chairs: Eiji Tanaka\**

*(Department of Gastroenterology and Nephrology and Hematology, Graduate School of Medicine, Shinshu University)*

*Etsuko Hashimoto*

*(Institute of Gastroenterology, Tokyo Womens Medical University)*

1. Epidemiology and Risk Factors of HCC

Namiki Izumi\*

(Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital)

2. Prevention of HCC development from HBV infection

Hiroshi Yatsunami\*

(Clinical Research Center, National Hospital Organization Nagasaki Medical Center)

3. Prevention of hepatocellular carcinoma in patients with hepatitis C

Tetsuo Takehara

(Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine)

4. Prevention for HCC from NASH/NAFLD

Hitoshi Yoshiji

(Third Department of Internal Medicine, Nara Medical University)

5. Retinoid signal as an important player for prevention of hepatocellular carcinoma

Goshi Shiota

(Department of Molecular Genetics and Regenerative Therapeutics, Tottori University, Japan)

14:50~16:50 at Conference Room 2

**Session 12 Diagnosis for HCC**

*Chairs: Osamu Matsui*

*(Professor Emeritus, Kanazawa University)*

*Hiroko Iijima*

*(Ultrasound Imaging Center, Department of Internal Medicine, Division of Hepatobiliary and Pancreatic Disease, Hyogo College of Medicine)*

1. Sophisticated use of tumor markers for the diagnosis of hepatocellular carcinoma

Hidenori Toyoda

(Department of Gastroenterology, Ogaki Municipal Hospital)

2. Japanese Surveillance Protocol

Ryosuke Tateishi

(Department of Gastroenterology, The University of Tokyo Graduate School of Medicine)

3. Contrast enhanced ultrasound in the diagnosis of hepatocellular carcinoma

Takashi Nishimura

(Ultrasound Imaging Center, Department of Internal Medicine, Division of Hepatobiliary and Pancreatic Disease, Hyogo College of Medicine)

4. Diagnosis of HCC using Dynamic CT / IVR-CT

Satoshi Kobayashi

(Department of Quantum medical technology, Kanazawa University Graduate School of Medical Sciences)

5. Current MR Imaging of Hepatocellular Carcinoma

Yasunari Fujinaga

(Department Radiology, Shinshu University)

6. Diagnosis for HCC, EOB-MRI as functional imaging

Norihide Yoneda

(Department of Radiology, Kanazawa University Hospital)

15:35~16:50 at Conference Room 1

### **Distinguished Poster Presentation**

*Chair: Masao Honda*

*(Department of Gastroenterology, Kanazawa University Graduate School of Medical Sciences)*

**DP-1. Two-step forward genetic screens in mice identifies multiple hepatocellular carcinoma driver genes and a new therapeutic target**

Takahiro Kodama

(Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine)

**DP-2. Comprehensive Analysis of Gene Mutations in Liver Cancer Stem Cells**

Takehiro Hayashi

(Disease Control and Homeostasis, Division of Environmental Science, Kanazawa University Graduate School of Medical Science)

**DP-3. Activated fibroblasts recovered from cancer tissue and cirrhotic liver are primed to exert malignancy prone functions in HCC**

Yohei Mano

(National Center for Global Health and Medicine / Department of Surgery and Science, Kyushu University, Fukuoka, Japan)

**DP-4. High-dose cyclophosphamide Eradicates Hepatoma Cells by rapid recruitment of CD4<sup>+</sup> cytolytic T cells into tumor sites via the CCL3/CCR5 axis**

Tatsushi Naito

(Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui / Division of Molecular Bioregulation, Cancer Research Institute, Kanazawa University)

**DP-5. Roles of connective tissue growth factor (CTGF) in tumor-stroma interaction in hepatocellular carcinoma and the therapeutic potential of anti-CTGF neutralizing antibody.**

Yuki Makino

(Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan)

16:50~17:10

### **Awards Ceremony and Closing Remark**

Shuichi Kaneko (President of the Conference)

## POSTER PRESENTATION & DISCUSSION

September 22<sup>nd</sup> (Thursday), 2016 16:50~17:50

No. Title Author

### Basic Research-1

16:50~17:20

Chair: *Tsutomu Masaki*

*(Department of Gastroenterology and Neurology Faculty of Medicine, Kagawa University)*

- |      |   |                  |
|------|---|------------------|
| P-01 | Down-regulated acidic leucine-rich nuclear phosphoprotein 32 family member B (ANP32B) has a role in suppression of apoptosis, and is associated with poor prognosis in patients with hepatocellular carcinoma | Yoshinori Ohno   |
| P-02 | NASH-related liver tumorigenesis is suppressed in mice lacking hepatic retinoid storage   | Yohei Shirakami  |
| P-03 | Continuous hepatocyte apoptosis accelerates diethylnitrosamine-induced liver tumor development  | Yasutoshi Nozaki |
| P-04 | TPU0114 suppresses mTOR signaling pathway in human hepatocellular carcinoma   | Tomoyuki Hayashi |
| P-05 | Wnt/beta-catenin signaling activates dUTP pyrophosphatase to prevent DNA damages in human liver cancer stem cells   | Yoshiro Asahina  |

### Basic Research-2

17:20~17:50

Chair: *Kazuto Nishio*

*(Department of Genome Biology, Kindai University School of Medicine)*

- |      |   |                    |
|------|---|--------------------|
| P-06 | Suppression of tumor progression in patients with advanced stage of hepatocellular carcinoma by CCL1 ODN gene therapy                             | Akira Asai         |
| P-07 | Dual therapy with acyclic retinoid and angiotensin-II receptor1 blocker attenuates chemically induced hepatocarcinogenesis in diabetic OLETF rats | Norihisa Nishimura |
| P-08 | Sorafenib targets CD90+ cancer stem cells and controls distant metastasis.  | Mariko Yoshida     |
| P-09 | Emergence of mesenchymal stem-like CD105+ cancer cells de novo after chemotherapy in human hepatocellular carcinoma.                              | Yoshimoto Nomura   |
| P-10 | The roles of Protein kinase R and its possibility as a therapeutic target in hepatocellular carcinoma with hepatitis C virus infection            | Takao Watanabe     |

**Epidemiology and diagnosis**

16:50~17:26

*Chair: Hitoshi Yoshiji**(Third Department of Internal Medicine, Nara Medical University)*

- |      |  |                   |
|------|--|-------------------|
| P-11 | SMR distribution of HCC in Japan, 1970-2010  | Tomoyuki Akita    |
| P-12 | Current status of alcoholic hepatocellular carcinoma in Japan - Nationwide survey in 2014  | Yoshinori Horie   |
| P-13 | The differential diagnostic ability of hepatocellular carcinoma using shear wave elastography                                      | Takashi Nishimura |
| P-14 | The role of contrast enhanced ultrasound for hypovascular liver tumor detected by Gd-EOB-DTPA MRI                                  | Tomoko Aoki       |
| P-15 | Examination of hepatocellular carcinoma according to cause in our and affiliated hospitals   | Masao Iwao        |
| P-16 | The situation of Epidemiology, diagnosis and treat liver cancer (HCC) at the Haiphong Oncology Centre in VietNam from 2010 to 2015 | Nguyen Lam Hoa    |

**TACE-1**

17:26~17:50

*Chair: Kenji Ikeda**(Department of Hepatology, Toranomon Hospital, Tokyo, Japan)*

- |      |  |                  |
|------|--|------------------|
| P-17 | Tumor number is the most important factor to predict early recurrence post TACE in hepatocellular carcinoma  | Akitoshi Douhara |
| P-18 | Usefulness of sub-classification of intermediate stage hepatocellular carcinoma  | Yutaka Yasui     |
| P-19 | Switching the Platinum Agents in Transarterial Infusion Chemotherapy with and without Embolization for Patients with Intermediate and/or Advanced Stage Hepatocellular Carcinoma | Taku Chikayama   |
| P-20 | Changes in levels of venous blood ketone bodies after transcatheter arterial chemoembolization of hepatocellular carcinoma   | Ryu Sasaki       |

## TACE-2

16:50~17:20

Chair: *Tetsuya Minami*

*(Department of Radiology, Kanazawa University Graduate School of Medical Sciences)*

- |      |   |                   |
|------|---|-------------------|
| P-21 | Effects of drug-eluting bead transarterial chemoembolization on giant hepatocellular carcinoma: A retrospective study   | Ken Okai          |
| P-22 | Effectiveness of Cisplatin eluting beads TACE for Early / Intermediate stage HCC  | Takayoshi Oikawa  |
| P-23 | Comparison of therapeutic effect of sorafenib and drug eluting beads transcatheter arterial chemoembolization on hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization | Yasuyuki Tomiyama |
| P-24 | Efficacy of balloon-occluded transcatheter arterial chemoembolization (B-TACE) for hepatocellular carcinoma which is unresponsive to conventional transcatheter arterial chemoembolization (C-TACE)           | Takeshi Hatanaka  |
| P-25 | The effectiveness of 3D navigation system for transarterial chemoembolization in patients with hepatocellular carcinoma   | Tsutomu Tamai     |

## Tumor markers and Biomarkers-1

17:20~17:50

Chair: *Kenichi Harada*

*(Department of Human Pathology, Kanazawa University Graduate School of Medicine)*

- |      |  |                   |
|------|--|-------------------|
| P-26 | Methylation of <i>SOX1</i> and <i>VIM</i> Promoters in the Serum as Potential Biomarkers for Hepatocellular Carcinoma                        | Kai Wang          |
| P-27 | Peripheral blood mononuclear cells A20 mRNA level is a convincing biomarker for hepatocellular carcinoma                                     | Yu-Chen Fan       |
| P-28 | Pro-angiogenic Tie2-expressing monocytes/TEMs as a biomarker of the response to sorafenib in patients with advanced hepatocellular carcinoma | Hiroataka Shoji   |
| P-29 | Significance of hepatic progenitor cell marker-positive hepatocellular carcinoma and its possible prediction by AFP-L3                       | Atsunori Tsuchiya |
| P-30 | Changes of Immunoglobulin-bound Glycans in Patients with Hepatocellular carcinoma  | Chihiro Dohi      |



**Tumor markers and Biomarkers-2**

16:50~17:26

*Chair: Tatsuya Kanto*

*(National Center for Global Health and Medicine)*

- |      |   |                  |
|------|---|------------------|
| P-31 | Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein may predict liver fibrosis and progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection | Satoru Joshita   |
| P-32 | Hepatocellular Carcinoma Suppressor 1 (HCCS1) Promoter Methylation as Biomarker for Hepatocellular Carcinoma Associated with Hepatitis B.   | Kai Wang         |
| P-33 | The Impact of HCV eradication by direct-acting antivirals on Lens culinaris agglutinin-reactive fraction of AFP   | Yoshinari Asaoka |
| P-34 | The features of hepatocellular carcinoma after IFN-free treatment of hepatitis C  | Masanori Tokoro  |
| P-35 | Hepatocellular carcinoma development in hepatitis C virus patients who achieved sustained viral response by interferon therapy and direct anti-viral agents therapy                                   | Yuko Nagaoki     |
| P-36 | Risk factors for hepatocellular carcinoma after interferon-free therapy for hepatitis C virus   | Seiichi Mawatari |

## Curative treatment-1

16:50~17:20

Chair: Masaaki Shiina

(Department of Gastroenterology and Hepatology, Shin-Yurigaoka General Hospital)

- |      |   |                |
|------|---|----------------|
| P-37 | Surgical indication for hepatocellular carcinoma with tumor thrombus in inferior vena cava                                | Etsuro Hatano  |
| P-38 | Radiofrequency ablation for the treatment of Intermediate stage hepatocellular carcinoma                                  | Kazuhiro Nouse |
| P-39 | The efficacy of radiofrequency ablation for the patients with BCLC stage B hepatocellular carcinoma - Multi-center study. | Yohei Koizumi  |
| P-40 | Adaptation and limitation of RFA along the guideline of HCC treatment in the clinical practice                            | Shinya Sato    |
| P-41 | Safety and survival of Radiofrequency ablation for elderly patients with hepatocellular carcinoma                         | Junya Oribe    |

## Curative treatment-2

17:20~17:50

Chair: Masataka Seike

(Department of Gastroenterology, Faculty of Medicine, Oita University)

- |      |  |                 |
|------|--|-----------------|
| P-42 | Safe and efficient Radiofrequency ablation based on the characteristics of various devices   | Naoki Morimoto  |
| P-43 | US-US fusion imaging in radiofrequency ablation therapy for hepatocellular carcinoma   | Yasunori Minami |
| P-44 | Analysis of the factors for intrahepatic recurrence of hepatocellular carcinoma after radiofrequency ablation  | Michihito Murao |
| P-45 | Impact of sustained virological response to interferon therapy for chronic hepatitis C on recurrence-free survival in patients with hepatocellular carcinoma | Hiroji Shinkawa |
| P-46 | Short-term change in liver function following HCC treatment after DAA treatment  | Koichi Honda    |

**Chemotherapy-1**

16:50~17:20

*Chair: Shinji Tanaka**(Department of Molecular Oncology, Tokyo Medical and Dental University)*

- P-47 Regorafenib inhibits ERK signaling and suppresses the growth of sorafenib-resistant cells in human hepatocellular carcinoma Tomomi Hashiba
- P-48 Involvement of autophagy regulated by microRNAs in the resistance to sorafenib in hepatocellular carcinoma Takayuki Kogure
- P-49 Different serum cytokine/chemokine/growth factor profiles correlate with responses to sorafenib and cytotoxic agents in human hepatocellular carcinoma Tsuyoshi Suda
- P-50 TSU-68 ameliorates the aggressiveness of hepatocellular carcinoma through inhibition of microenvironmental PDGF receptor signaling Yasumasa Hara
- P-51 Sulfasalazine targets the xCT-CD44v9 system sensitizing aggressive liver cancer cells to oxidative stress Fumitaka Wada

**Chemotherapy-2 and Others**

17:20~17:50

*Chair: Hiroshi Aikata**(Department of Gastroenterology and Metabolism, Hiroshima University Hospital)*

- P-52 Hepatic arterial infusion chemotherapy using fine powder formulation of CDDP suspended in Lipiodol combined with 5-FU for advanced hepatocellular carcinomas with macroscopic vascular invasion Takashi Niizeki
- P-53 Usefulness of ACTH (Assessment for Continuous Treatment with Hepatic arterial infusion chemotherapy) score in patients with advanced hepatocellular carcinoma Issei Saeki
- P-54 Efficacy of hepatic arterial infusion chemotherapy with cisplatin for second-line treatment after sorafenib in hepatocellular carcinoma patients Masaaki Kondo
- P-55 Efficacy and safety of stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. Tomokazu Kawaoka
- P-56 A case of hepatitis C related hepatocellular carcinoma developed tumor growth and recurrence during direct acting antivirals treatment Suguru Horiguchi